InvestorsHub Logo
Followers 30
Posts 5063
Boards Moderated 0
Alias Born 01/07/2020

Re: None

Monday, 05/08/2023 5:40:19 AM

Monday, May 08, 2023 5:40:19 AM

Post# of 426486
Here an interesting post from YH - from an insider of the med system in US.

Thanks to Greg

This message is directed towards Amarin management. I am a primary care physician on the front lines of our healthcare system. I continue to be amazed by how under prescribed Vascepa has been. This is despite its FDA approval and endorsement by many cardiology, lipidology, and endocrinology organizations. When I ask my cardiology colleagues why they are not prescribing it, it’s not necessarily that they don’t believe in the science, rather, it is because of coverage issues.
When you prescribe a medication and it continually gets denied, you give up, and stop prescribing it. I think it is a big obstacle in the growth of Vascepa. There needs to be a large scale educational program directed toward insurance companies to let them know how, unlike many of the other newer drugs, Vascepa is actually cost-effective. If every patient that qualifies for Vascepa starts using it, it will save millions of lives and save the healthcare system millions of dollars. What’s the problem???

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News